atai Impact, the recently launched philanthropic program of atai
Life Sciences (Nasdaq: ATAI) (“atai”), today announced its first
major initiative, the establishment of the atai Fellowship Fund in
Psychedelic Neuroscience (“atai Fellowship Fund”) in collaboration
with Massachusetts General Hospital’s (MGH) Center for the
Neuroscience of Psychedelics.
atai Impact was launched in October 2021 by atai Life Sciences,
a clinical-stage biopharmaceutical company, to harness the power of
innovative mental health approaches for positive social change.
atai Impact is committed to advancing education, expanding access,
and supporting the wider ecosystem of mental health care, with an
initial focus on psychedelics.
The $2 million atai Fellowship Fund will facilitate further
research into the potential of psychedelics to address unmet
patient needs in mental health and support promising graduate
students in furthering their professional careers in this emerging
field.
Massachusetts General Hospital was selected as the ideal partner
for the atai Fellowship Fund due to its global reputation as a
leading academic medical center and position as the largest
teaching hospital of Harvard Medical School. This Fellowship builds
on existing collaborations between atai Life Sciences and the
Center for Neuroscience of Psychedelics, announced in January 2021,
to accelerate discovery of the mechanisms underlying the
therapeutic effects of psychedelic agents.1
Fellows will have access to MGH’s cutting-edge resources and
expertise in neuroimaging technologies, cognitive neuroscience,
cellular and molecular neurobiology, and clinical trial design. The
Fund will enable them to pursue the discovery, optimization, and
translation of novel experimental psychedelic neurotherapeutics.
The ultimate objective of the Fund will be to investigate and
unlock the potential of psychedelics to improve brain health and
reduce the burden of mental health conditions, which affect over a
billion people worldwide.2
Fellows will be selected with a focus on diversity, equity and
inclusion and mentored by leading scientists from across key
departments of Massachusetts General Hospital, including Neurology,
Psychiatry and Radiology. Fellows will be equipped to explore a
variety of therapies and neurotherapeutics, and their potential to
address key mental health needs, in a world-class educational
environment.
“We are very proud to kick off the atai Impact initiatives with
such an important contribution to drive robust psychedelic medicine
research and to do so with the eminent team at Massachusetts
General Hospital,” said Florian Brand, Chief Executive Officer and
Co-founder of atai Life Sciences.
“Through the atai Impact Fellowship Fund, we are excited to be
fostering the next generation of neuro-innovators. We look forward
to the future findings of their research, and its important
contribution to the emerging psychedelic renaissance and the future
of global mental health care.”
“The current development of psychedelics as psychiatric
therapeutics is the beginning, not the end of the story,” said
Jerrold F. Rosenbaum, MD, Director, Center for the Neuroscience of
Psychedelics at Massachusetts General Hospital.
“These agents are forerunners to a future of novel compounds
that will depend on the advance of science to lead to deeper
understanding of the underlying neuroscience to deliver enhanced
and more precise treatments. For this we need a new generation of
scientists and for this goal, the atai Fellowship will be an
essential contribution.”
About atai Impact
atai Impact was launched by atai Life Sciences, in October
2021, to harness the power of innovative mental health approaches
for positive social change.
The key pillars of atai Impact’s activities are: advancing
education, expanding access, and supporting the wider ecosystem of
mental health care. atai Impact has an initial focus on the
psychedelics sector, given its emerging potential in tackling the
growing mental health crisis.
The establishment of atai Impact is based on atai Life
Sciences’ position that harmonization across commercial and
non-profit entities represents the best path forward to address all
aspects of the escalating global mental crisis.
About atai Life Sciences
atai is a clinical-stage biopharmaceutical company aiming to
transform the treatment of mental health disorders. atai was
founded in 2018 as a response to the significant unmet need and
lack of innovation in the mental health treatment landscape. atai
is dedicated to acquiring, incubating and efficiently developing
innovative therapeutics to treat depression, anxiety, addiction,
and other mental health disorders.
atai's business model combines funding, technology, scientific
and regulatory expertise with a focus on psychedelic therapy and
other drugs with differentiated safety profiles and therapeutic
potential. By pooling resources and best practices, atai aims to
responsibly accelerate the development of new medicines across its
companies, seeking to effectively treat and ultimately heal mental
health disorders.
atai's vision is to heal mental health disorders so that
everyone, everywhere can live a more fulfilled life. atai has
offices in New York, London, and Berlin. For more information,
please visit www.atai.life.
References:
- atai Life Sciences to Collaborate with Massachusetts General
Hospital to Accelerate Discovery of Mechanisms Underlying
Therapeutic Effects of Psychedelic Agents. [Press Release]
https://ir.atai.life/news-releases/news-release-details/atai-life-sciences-collaborate-massachusetts-general-hospital.
Published January 26, 2021. Accessed November 12, 2021.
- Rehm J, Shield KD. Global Burden of Disease and the Impact of
Mental and Addictive Disorders. Curr Psychiatry Rep.
2019;21(2):10.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Any express or implied statements contained in this press
release (including without limitation, the atai Impact program and
any other future philanthropic endeavors by atai) that are not
statements of historical fact may be deemed to be forward-looking
statements. Forward-looking statements are neither promises nor
guarantees, but involve known and unknown risks and uncertainties
that could cause actual results to differ materially from those
projected, including, without limitation, the important factors
discussed under the caption “Risk Factors” in atai's prospectus
pursuant to Rule 424(b) filed with the U.S. Securities and Exchange
Commission (“SEC”) on June 21, 2021, and in atai’s other filings
with the SEC. atai disclaims any obligation or undertaking to
update or revise any forward-looking statements contained in this
press release, other than to the extent required by applicable
law.
Contact Information
For atai Impact:Email: Impact@atai.life
For atai:Media Contact:Camilla DormerVP,
Communications, atai Life SciencesEmail: camilla@atai.life
Investor Contact:Chad MesserVP, Investor Relations, atai Life
SciencesEmail: chad@atai.life
ATAI Life Sciences NV (NASDAQ:ATAI)
Historical Stock Chart
From Jun 2024 to Jul 2024
ATAI Life Sciences NV (NASDAQ:ATAI)
Historical Stock Chart
From Jul 2023 to Jul 2024